Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Enlicitide Decanoate Formulations
NCT06691906Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of enlicitide in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from 0 to 24 hours, Area Under the Concentration-Time Curve from 0 to Time of Last Quantifiable Sample and 6 more. Started Mar 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06691906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06691906.